Louai Labanieh
Overview
Explore the profile of Louai Labanieh including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
2296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yamada-Hunter S, Theruvath J, McIntosh B, Freitas K, Lin F, Radosevich M, et al.
Nature
. 2024 May;
630(8016):457-465.
PMID: 38750365
Adoptively transferred T cells and agents designed to block the CD47-SIRPα axis are promising cancer therapeutics that activate distinct arms of the immune system. Here we administered anti-CD47 antibodies in...
2.
Yang J, Yamada-Hunter S, Labanieh L, Sotillo E, Cheah J, Roberts D, et al.
Proc Natl Acad Sci U S A
. 2024 Mar;
121(13):e2320053121.
PMID: 38513100
Lysosome-targeting chimeras (LYTACs) are a promising therapeutic modality to drive the degradation of extracellular proteins. However, early versions of LYTAC contain synthetic glycopeptides that cannot be genetically encoded. Here, we...
3.
Klysz D, Fowler C, Malipatlolla M, Stuani L, Freitas K, Chen Y, et al.
Cancer Cell
. 2024 Jan;
42(2):266-282.e8.
PMID: 38278150
Adenosine (Ado) mediates immune suppression in the tumor microenvironment and exhausted CD8 CAR-T cells express CD39 and CD73, which mediate proximal steps in Ado generation. Here, we sought to enhance...
4.
Yang J, Yamada-Hunter S, Labanieh L, Sotillo E, Cheah J, Roberts D, et al.
bioRxiv
. 2023 Nov;
PMID: 38014030
Lysosome-targeting chimeras (LYTACs) are a promising therapeutic modality to drive the degradation of extracellular proteins. However, early versions of LYTAC contain synthetic glycopeptides that cannot be genetically encoded. Here we...
5.
6.
Klysz D, Fowler C, Malipatlolla M, Stuani L, Freitas K, Meier S, et al.
bioRxiv
. 2023 May;
PMID: 37162847
Adenosine (Ado) mediates immune suppression in the tumor microenvironment and exhausted CD8 CAR T cells mediate Ado-induced immunosuppression through CD39/73-dependent Ado production. Knockout of CD39, CD73 or A2aR had modest...
7.
Tousley A, Rotiroti M, Labanieh L, Rysavy L, Kim W, Lareau C, et al.
Nature
. 2023 Mar;
615(7952):507-516.
PMID: 36890224
Although chimeric antigen receptor (CAR) T cells have altered the treatment landscape for B cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development for solid tumours because...
8.
Labanieh L, Mackall C
Nature
. 2023 Feb;
614(7949):635-648.
PMID: 36813894
The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and plasma cell malignancies has validated the use of this therapeutic class for liquid cancers, but resistance...
9.
Labanieh L, Majzner R, Klysz D, Sotillo E, Fisher C, Vilches-Moure J, et al.
Cell
. 2022 Apr;
185(10):1745-1763.e22.
PMID: 35483375
Regulatable CAR platforms could circumvent toxicities associated with CAR-T therapy, but existing systems have shortcomings including leakiness and attenuated activity. Here, we present SNIP CARs, a protease-based platform for regulating...
10.
Grosskopf A, Labanieh L, Klysz D, Roth G, Xu P, Adebowale O, et al.
Sci Adv
. 2022 Apr;
8(14):eabn8264.
PMID: 35394838
Adoptive cell therapy (ACT) has proven to be highly effective in treating blood cancers, but traditional approaches to ACT are poorly effective in treating solid tumors observed clinically. Novel delivery...